RG+A Debuts Treatment Decision Simulation Approach

In the US, healthcare MR and consulting firm RG+A has introduced a research approach to help forecasters predict the performance of products that have complex treatment protocols.

RG+A uses both primary research and consulting services to advise pharma, biotech and medical device companies on market valuation, pricing and strategy; and offers proprietary forecasting and simulation techniques, models and tools for converting results into action.

The new service, known as Dynamic Practice Simulation Line of Therapy, simulates the treatment decision process by presenting physicians with a set of patient profiles in a given treatment area, getting them to treat the patients, and then receiving feedback after each treatment, on its effectiveness. Treatment decisions are assessed over three lines of therapy, and physicians make their treatment decisions under two scenarios: the market as it currently exists, and a future market after the launch of a new treatment.

Bruce Duncan (pictured), RG+A's Chief Research Scientist, comments: 'Simulating decision making with a feedback loop provides an ideal vehicle for assessing and understanding diseases with high rates of misdiagnosis, understanding the testing sequence physicians use when faced with symptoms that could represent many diseases, or monitoring the treatment protocol with a rapidly deteriorating patient'.

Web site: www.thinkrga.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.